Kiniksa Pharmaceuticals International (KNSA) EBIAT (2021 - 2025)
Kiniksa Pharmaceuticals International (KNSA) has disclosed EBIAT for 5 consecutive years, with $14.2 million as the latest value for Q4 2025.
- For the quarter ending Q4 2025, EBIAT rose 259.75% year-over-year to $14.2 million, compared with a TTM value of $59.0 million through Dec 2025, up 236.61%, and an annual FY2025 reading of $59.0 million, up 236.61% over the prior year.
- EBIAT was $14.2 million for Q4 2025 at Kiniksa Pharmaceuticals International, down from $18.4 million in the prior quarter.
- Across five years, EBIAT topped out at $224.1 million in Q3 2022 and bottomed at -$49.5 million in Q1 2021.
- Average EBIAT over 5 years is $2.8 million, with a median of -$10.6 million recorded in 2023.
- The sharpest move saw EBIAT skyrocketed 833.67% in 2022, then plummeted 135.22% in 2024.
- Year by year, EBIAT stood at -$36.3 million in 2021, then surged by 112.28% to $4.5 million in 2022, then surged by 465.73% to $25.2 million in 2023, then crashed by 135.22% to -$8.9 million in 2024, then surged by 259.75% to $14.2 million in 2025.
- Business Quant data shows EBIAT for KNSA at $14.2 million in Q4 2025, $18.4 million in Q3 2025, and $17.8 million in Q2 2025.